Drug Profile
XTX 202
Alternative Names: XTX-202Latest Information Update: 08 Nov 2023
Price :
$50
*
At a glance
- Originator Akriveia Therapeutics
- Developer Xilio Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 03 Nov 2023 XTX 202 is available for licensing as of 03 Nov 2023
- 03 Nov 2023 Interim pharmacodynamics, pharmacokinectics, adverse events and efficacy data from a phase-I/II trial in Solid tumours released by Xilio Therapeutics
- 09 May 2023 Phase-II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral) (NCT05052268)